101,125 Shares in Verrica Pharmaceuticals Inc. $VRCA Acquired by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC purchased a new position in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 101,125 shares of the company’s stock, valued at approximately $45,000. Kovitz Investment Group Partners LLC owned approximately 0.11% of Verrica Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of VRCA. Invesco Ltd. acquired a new position in Verrica Pharmaceuticals during the 4th quarter worth approximately $32,000. Charles Schwab Investment Management Inc. grew its stake in Verrica Pharmaceuticals by 127.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company’s stock valued at $44,000 after purchasing an additional 55,852 shares in the last quarter. Bank of America Corp DE grew its stake in Verrica Pharmaceuticals by 347.5% during the 4th quarter. Bank of America Corp DE now owns 143,818 shares of the company’s stock valued at $101,000 after purchasing an additional 111,678 shares in the last quarter. Renaissance Technologies LLC grew its stake in Verrica Pharmaceuticals by 57.7% during the 4th quarter. Renaissance Technologies LLC now owns 233,300 shares of the company’s stock valued at $163,000 after purchasing an additional 85,336 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Verrica Pharmaceuticals by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 477,269 shares of the company’s stock valued at $334,000 after purchasing an additional 21,789 shares in the last quarter. 42.45% of the stock is owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Trading Down 4.7%

Shares of Verrica Pharmaceuticals stock opened at $5.47 on Friday. The business’s 50 day simple moving average is $6.62 and its 200-day simple moving average is $6.00. The stock has a market capitalization of $51.69 million, a price-to-earnings ratio of -0.66 and a beta of 1.92. Verrica Pharmaceuticals Inc. has a twelve month low of $3.82 and a twelve month high of $29.70.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings results on Tuesday, August 12th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.72. The company had revenue of $12.70 million for the quarter, compared to analyst estimates of $4.37 million. Sell-side analysts predict that Verrica Pharmaceuticals Inc. will post -1.46 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on VRCA shares. Needham & Company LLC restated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, May 14th. Wall Street Zen upgraded Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Verrica Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $80.00.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.